Access the full text.
Sign up today, get DeepDyve free for 14 days.
C.L. Shapiro, T. Ervin, L. Welles (1999)
Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancerJ Clin Oncol, 17
D.J. Slamon, B. Leyland-Jones, S. Shak (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344
M. O'brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. Kieback, P. Tomczak, S. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 15 3
A. Tulpule, B. Espina, N. Berman, L. Buchanan, W. Boswell, L. Welles, A. Levine (2001)
A phase I/II trial of liposomal doxorubicin (tlc-d99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (comp) for newly diagnosed intermediate and high grade non-Hodgkin's lymphoma (nhl)European Journal of Cancer, 37
L. Assersohn, S. Johnston (2003)
Postmenopausal Metastatic Breast CancerAmerican Journal of Cancer, 2
Lawrence Mayer, Marcel Bally, Pieter Cullis, S. Wilson, J. Emerman (1990)
Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.Cancer letters, 53 2-3
M. Marty (2001)
Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparisonThe Breast, 10
A. Hamilton, L. Biganzoli, R. Coleman, L. Mauriac, P. Hennebert, A. Awada, M. Nooij, L. Beex, M. Piccart, I. Hoorebeeck, P. Bruning, Dominique Valeriola (2002)
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 13 6
C. Swenson, W. Perkins, P. Roberts, A. Janoff (2001)
Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)The Breast, 10
Stephen Chan, N. Davidson, E. Juozaitytė, F. Erdkamp, A. Płużańska, N. Azarnia, L. Lee (2004)
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 15 10
P. Schmid, J. Krocker, A. Dieing (2003)
Gemcitabine, myocet and docetaxel for primary treatment of breast cancer [abstract no. v269]Onkologie, 26Suppl.5
Freddie Hamdy, Jenny Donovan, Athene, Chris Metcalfe, M. Davis, R. Martin, Bollina J., Andrew Doble, Alan Doherty, Gillatt, Gnanapragasam David, O. Hughes, Howard, A. Paul, E. Paez, P. Powell, M. Mason, J. Oxley, J. Lane, M. Davis, E. Turner, G. Young, E. Walsh, R. Bryant, P. Bollina, D. Gillatt, V. Gnanapragasam, O. Hughes, R. Kockelbergh, H. Kynaston, E. Paez, P. Powell, D. Rosario, E. Rowe, M. Mason, T. Peters, J. Oxley, N. Williams, J. Staffurth, D. Neal (2023)
The n e w e n g l a n d j o u r n a l of m e d i c i n e
J. Crown, V. Diéras, M. Kaufmann, G. Minckwitz, S. Kaye, R. Leonard, M. Marty, J. Misset, B. Osterwalder, M. Piccart (2002)
Chemotherapy for metastatic breast cancer-report of a European expert panel.The Lancet. Oncology, 3 12
A. Hamilton, L. Biganzoli, R. Coleman (2002)
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancerAnn Oncol, 13
V. Pai, M. Nahata (2000)
Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 22
G. Batist, L. Harris, N. Azarnia (2000)
Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin [abstract no. 405]Proc Am Soc Clin Oncol, 19
C. Chung, R. Carlson (2003)
Goals and objectives in the management of metastatic breast cancer.The oncologist, 8 6
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
M. Federico, M.J.S. Dyer, M.D. Caballero (2004)
The MYOCAN study: a phase II study of cyclophosphamide, oncovin, Myocet™, and prednisone plus rituximab (R-COMP) in the treatment of elderly patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) [abstractno. 4586]Blood, 104
L. Harris, G. Batist, R. Belt, Douglas Rovira, R. Navari, N. Azarnia, L. Welles, E. Winer (2002)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 94
K. Mross, B. Niemann, U. Massing, J. Drevs, C. Unger, R. Bhamra, C. Swenson (2004)
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose studyCancer Chemotherapy and Pharmacology, 54
C. Swenson, L. Bolcsak, G. Batist, T. Guthrie, K. Tkaczuk, H. Boxenbaum, L. Welles, S. Chow, R. Bhamra, P. Chaikin (2003)
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerAnti-Cancer Drugs, 14
G. Batist, J. Barton, P. Chaikin, C. Swenson, L. Welles (2002)
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapyExpert Opinion on Pharmacotherapy, 3
P. Roberts, A.S. Janoff, E. Mayhew (2000)
Doxorubicin fluorescence in a human breast carcinoma (MX-1), after treatment with liposome-associated or free doxorubicin [abstract no. 3327]Proc Am Assoc Cancer Res, 41
D. Iannitti, R. Rathore, H. Safran (2000)
TLC D-99 can be safely administered to patients with advanced hepatobiliary carcinomas and severe hepatobiliary dysfunction [abstract no. 1214]Proc Am Soc Clin Oncol, 20
A. Levine, A. Tulpule, B. Espina, A. Sherrod, W. Boswell, R. Lieberman, B. Nathwani, L. Welles (2004)
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 13
E. Rivera (2003)
Liposomal anthracyclines in metastatic breast cancer: clinical update.The oncologist, 8 Suppl 2
G. Batist, G. Ramakrishnan, C. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, Pankaj Shah, A. Khojasteh, M. Nair, K. Hoelzer, K. Tkaczuk, Youn Park, Lily Lee (2001)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 5
M. Theodoulou, S.M. Campos, G. Batist (2002)
TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis [abstract no. 216]Proc Am Soc Clin Oncol, 21
T. Safra (2003)
Cardiac safety of liposomal anthracyclines.The oncologist, 8 Suppl 2
L. Assersohn, S.R.D. Johnston (2003)
Postmenopausal metastatic breast cancer: a review of first-line treatment optionsAm J Cancer, 2
G. Batist (2001)
Improving the therapeutic index when using Myocet™ in the treatment of metastatic breast cancerThe Breast, 10
V.B. Pai, M.C. Nahata (2000)
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and preventionDrug Saf, 22
J. Cortes, M. Climent, A. Lluch (2004)
Updated results of a phase II study (M77035) of Myocet® combined with weekly Herceptin ®and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC) [abstract no. 3041]Breast Cancer Res Treat, 88
S. Swain, F. Whaley, M. Ewer (2003)
Congestive heart failure in patients treated with doxorubicinCancer, 97
V. Valero, A.U. Buzdar, R.L. Theriault (1999)
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancerJ Clin Oncol, 17
anthracycline doxorubicin by reducing the drug’s cardiotoxicity, but maintaining its antitumor efficacy. Liposomal doxorubicin plus cyclophosphamide is no less effective than conventional doxorubicin or epirubicin plus cyclophosphamide in the first-line treatment of women with metastatic breast cancer. In addition, the drug is significantly less cardiotoxic than conventional doxorubicin. The median cumulative dose to the first cardiac event for liposomal doxorubicin is higher than that for conventional doxorubicin; the potential to use dox- orubicin for a longer period of time may benefit a number of patients. Liposomal doxorubicin has also shown potential as part of a chemotherapy regimen in patients with non-Hodgkin lymphoma (NHL). Thus, liposomal doxorubicin represents an important advance in terms of offering reduced cardiotoxicity compared with conventional doxorubicin, and can be used in preference to conventional doxorubicin in a combination regimen with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. The rationale used as the basis for the design of intravenous liposomal doxorubicin is that the liposomes cannot Pharmacologic exit the circulation in healthy tissues, but can exit through leaky tumor-associated vessels. In animal models, Properties liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, and reduces mammary tumor growth to a significantly greater extent
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.